Rat HCC tumor cells transfected with CEACAM1a-4L displayed a significant decrease in tumor formation, progression, and burden compared to rat HCC cells transfected with CEACAM1b-4S and the negative control group, suggesting that CEACAM1 splice-switching therapy may inhibit HCC [96]. Here, CEACAM1 is linked to neoplasm.